SCHEMBL30723345

SCHEMBL30723345

Cc1ccc(C)c(S(=O)(=O)Nc2cc(Sc3nc[nH]n3)c(O)c3ccccc23)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FSCN1 Q16658 5/20 0.69
▸ MEN1 O00255 5/20 0.61
▸ KMT2A Q03164 5/20 0.61
▸ HKDC1 Q2TB90 5/20 0.61
▸ MCL1 Q07820 5/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ MAPT P10636 4/20 0.61
▸ BLM P54132 4/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ LMNA P02545 3/20 0.61
▸ HPGD P15428 3/20 0.61
▸ POLB P06746 3/20 0.61
▸ THRB P10828 3/20 0.61
▸ KDM4C Q9H3R0 2/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ KEAP1 Q14145 6/20 0.56
▸ NFE2L2 Q16236 6/20 0.56
▸ G6PD P11413 3/20 0.53
▸ GAA P10253 3/20 0.53
▸ KDM4E B2RXH2 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15521868 1.00 FSCN1 (0.69) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL30723332 0.92 FSCN1 (0.69) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL15521832 0.92 FSCN1 (0.69) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL13510218 0.91 FSCN1 (0.57) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL15521808 0.90 FSCN1 (0.68) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL30723340 0.90 FSCN1 (0.68) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL13510207 0.90 FSCN1 (0.56) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL15521893 0.89 FSCN1 (0.54) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL13510154 0.87 FSCN1 (0.54) FSCN1MEN1KMT2AHKDC1MCL1
SCHEMBL13510146 0.87 KEAP1 (0.59) FSCN1MEN1KMT2AHKDC1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368657-A1 METHODS FOR INHIBITING FASCIN NOVITA PHARMACEUTICALS INC (US) 2025-12-04 — — US disclosed
US-12384791-B2 Methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC. (US) 2025-08-12 — — US disclosed
US-20240158402-A1 METHODS FOR INHIBITING FASCIN NOVITA PHARMACEUTICALS, INC. (US) 2024-05-16 — — US disclosed
US-11866440-B2 Methods for inhibiting fascin CORNELL UNIVERSITY (US) 2024-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158402-A1 METHODS FOR INHIBITING FASCIN FSCN1, NLN, TNNI3 FSCN1 1/4885MEN1 3123/4885KMT2A 4603/4885
US-12384791-B2 Methods for inhibiting fascin FSCN1, NLN, TNNI3 FSCN1 1/4885MEN1 3123/4885KMT2A 4603/4885
US-20250368657-A1 METHODS FOR INHIBITING FASCIN FSCN1, NLN, TNNI3 FSCN1 1/4885MEN1 3123/4885KMT2A 4603/4885
US-11866440-B2 Methods for inhibiting fascin FSCN1, NLN, TNNI3 FSCN1 1/4885MEN1 3123/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback